Aytu Biopharma (AYTU) Assets (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Assets data on file, last reported at $111.7 million in Q1 2026.

• Assets for Q1 2026 came in at $111.7 million, down 10.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.7 million (down 10.07% YoY), and the FY2025 annual result was $124.2 million, up 5.15% from the prior year.
• Assets fell to $111.7 million in Q1 2026 per AYTU's latest filing, from $122.0 million in the prior quarter.
• Over five years, Assets peaked at $168.8 million in Q1 2022 and troughed at $111.7 million in Q1 2026.
• A 5-year average of $131.3 million and a median of $128.9 million in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2022 and 2025: Assets slumped 48.2% in 2022, then advanced 7.91% in 2025.
• A 5-year view of Assets shows it stood at $141.4 million in 2022, then decreased by 7.2% to $131.2 million in 2023, then fell by 11.45% to $116.2 million in 2024, then gained by 4.97% to $122.0 million in 2025, then fell by 8.45% to $111.7 million in 2026.
• Business Quant data shows AYTU's Assets at $111.7 million in Q1 2026, $122.0 million in Q4 2025, and $125.0 million in Q3 2025.